Lansoprazole drug data and news

---

US court dismisses Abbott's action against Takeda  Mar 3, 2006
...in Chicago has dismissed an action by Abbott Laboratories against Takeda Pharmaceutical over their partnership in the production of lansoprazole, stating that ... - TMCnet

Legal Action Instituted by Abbott Against Takeda Dismissed  Mar 1, 2006
In its lawsuit, Abbott claimed, among other things, that Takeda allegedly has earned excessive profits from its supply of lansoprazole to TAP Pharmaceutical ... - Genetic Engineering News,

US District Court Dismisses Abbott Laboratories' Litigation ...  Mar 3, 2006
Abbott claimed that Takeda Pharmaceutical had unjustly earned profits from its supply of lansoprazole to TAP Pharmaceutical Product, a joint venture company ... - Medical News Today (press release),

Teva Reports Record Sales and Net Income for the Fourth Quarter ...  Feb 27, 2006
...comparable quarter, including Alendronate in the UK and The Netherlands, as well as some newly launched products in the UK such as Lansoprazole and Sertraline ... - Genetic Engineering News,

Rich Daly Joins TAP As Senior Marketing Executive  Feb 2, 2006
...be responsible for leading the overall marketing strategy and initiatives for TAP's current and future brands - including Prevacid(R) (lansoprazole) and Lupron ... - International News Service,

Rich Daly Joins TAP As Senior Marketing Executive  Feb 2, 2006
...be responsible for leading the overall marketing strategy and initiatives for TAP's current and future brands - including Prevacid(R) (lansoprazole) and Lupron ... - International News Service,

Abbott Reports Record Sales, Earnings and Cash Flow in 2005  Jan 25, 2006
7.8 (b) $233 10.4 Omnicef $189 27.5 --- -- $189 27.5 Synthroid $141 (0.1) $15 9.8 $156 0.8 Leuprolide --- -- $54 (0.2) $54 (0.2) Lansoprazole --- -- $41 1.7 ... - MSN Money

Santarus down; TAP ends sublicense pact  Jan 9, 2006
Santarus, which entered into the sublicense agreement with TAP in June 2002, had granted TAP the right to develop drugs based on its lansoprazole proton pump ... - BusinessWeek

Scottish Medicines Consortium Approves Zoton FasTab, The First And ...  Jan 14, 2006
The Scottish Medicines Consortium (SMC) has now recommended the proton pump inhibitor (PPI) Zoton FasTab® (lansoprazole oro-dispersible tablets), in ... - Medical News Today (press release),

New Treatment for Bleeding Ulcers Reduces Surgery, Death Rates  Jan 25, 2006
The trials compared three oral and/or intravenous PPIs — omeprazole, pantoprazole and lansoprazole — to either no drug treatment or alternative acid ... - EndoNurse,

Generics Give Originators Heartburn  Jan 20, 2006
Whether its Nexium's esomeprazole, Prilosec's omeprazole, Prevacid's lansoprazole, or Aciphex's rabeprazole sodium, all are included in a family known as ... - Motley Fool

Santarus Receives Notice From TAP Pharmaceutical Products Inc. Of ...  Jan 9, 2006
...develop, manufacture and sell products resulting from the use of the company's immediate-release proton pump inhibitor (PPI) technology with lansoprazole, a PPI ... - Genetic Engineering News,

Norwood Immunology - Phase II Clinical Trial - Melanoma Cancer ...  Nov 17, 2005
Company Limited of Osaka, Japan. TAP currently markets Lupron Depot and Prevacid(R) (lansoprazole). For more information about TAP ... - Business Wire (press release),

£1bn cost of non-prescription drugs  Sep 30, 2005
...and circulation problems. And the single most costly prescription drug last year was Lansoprazole, used to treat stomach ulcers. - Scotland on Sunday,

NHS drug costs edge towards £1bn  Sep 30, 2005
...circulation problems. The single most costly prescription drug last year was Lansoprazole, used to treat stomach ulcers. And ulcer ... - Scotsman,

Bacteria Linked To Heart Risk  Oct 7, 2005
...and metronidazole--along with an acid-lowering medicine such as Pepto-Bismol, ranitidine, cimetidine, famotidine, omprazole, pantoprazole and lansoprazole. ... - Saturday Evening Post,

Lost in translation  Oct 6, 2005
...hospitals. Examples include the drug Lansoprazole, used to treat stomach ulcers, being transcribed into popular holiday island Lanzarote. ... - Hearld 24,

Gastroesophageal Reflux Disease - Patients Suffer For Two Years ...  Sep 17, 2005
Aliment Pharmacol Ther 2005; 21: 739-746. 5.Castell D et al Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. ... - Medical News Today (press release),

PATIENTS SUFFER FOR TWO YEARS BEFORE SEEKING MEDICAL HELP  Sep 13, 2005
5.Castell D et al Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am J Gastroenterol 2002;97:575–83. ... - SourceWire (press release),

How do you spell relief for what ails you?  Sep 14, 2005
Acid Blockers (to relieve irritation and pain from gastric acid): Lansoprazole, Omeprazole, and ranitidine -- Folic acid (Vitamin B-9) Vitamin B-12 ... - Cochrane Times,

TAP Expands Gastroenterological Pipeline by Signing Licensing ...  Sep 8, 2005
...of Osaka, Japan. TAP markets Prevacid(R) (lansoprazole) and Lupron Depot(R) (leuprolide acetate for depot suspension). For more ... - PR Newswire (press release),

TAP Expands Gastroenterological Pipeline by Signing Licensing ...  Sep 8, 2005
...of Osaka, Japan. TAP markets Prevacid® (lansoprazole) and Lupron Depot® (leuprolide acetate for depot suspension). For more information ... - Yahoo! News (press release)

TAP Expands Gastroenterological Pipeline by Signing Licensing ...  09 Sep 2005
...of Osaka, Japan. TAP markets Prevacid(R) (lansoprazole) and Lupron Depot(R) (leuprolide acetate for depot suspension). For more ... - PharmaLive.com (press release),

Flamel loses another Micropump contract  Sep 6, 2005
...it was revealed that TAP Pharmaceutical Products has pulled out of deal to develop a formulation of its big-selling gastrointestinal drug lansoprazole based on ... - in-PharmaTechnologist,

TAP Initiates Phase III Studies for Investigational New ...  Aug 29, 2005
Licensed from Takeda Pharmaceutical Company Limited, TAK-390MR employs a new modified release (MR) technology on an enantiomer of lansoprazole. ... - Yahoo News (press release)

UPDATE 3-Takeda Prevacid's successor to start Phase 3 trial  Aug 30, 2005
...it to skip Phase II clinical trials because the molecular structure of TAK-390MR is a mirror image of Prevacid, known generically as lansoprazole, which had ... - Reuters

Takeda Pharmaceutical Starts Phase III Clinical Study of TAK-390MR ...  Aug 31, 2005
...the US. TAK-390 is a drug candidate for the treatment of peptic ulcer, which is based on a proton pump inhibitor lansoprazole. By ... - Japan Corporate News (press release),

Pain Management/GI Combination Pill Wins Patent 8/18/05  Aug 17, 2005
In an initial comparison of PN 100, a combination tablet of lansoprazole and naproxen, against naproxen and co-therapy of a PPI, they found a significant ... - Bioscience Technology,

American College of Gastroenterology Announces 2005 Junior Faculty ...  Aug 16, 2005
...of Osaka, Japan. TAP currently markets Lupron Depot(r) (leuprolide acetate for depot suspension) and Prevacid(r) (lansoprazole). ... - U.S. Newswire (press release),

Norwood Immunology -- Publication in Leading Scientific Journal  Aug 11, 2005
Company Limited of Osaka, Japan. TAP currently markets Lupron Depot and Prevacid(R) (lansoprazole). For more information about TAP ... - Genetic Engineering News,

James Le Fanu on the power of genes  Aug 18, 2005
...into the lungs. Within a week of starting the acid-suppressant drug Lansoprazole, "my cough had vanished", she writes. There are ... - Telegraph.co.uk,

TAP Expands Gastroenterological Pipeline by Signing Licensing ...  08 Sep 2005
...of Osaka, Japan. TAP markets Prevacid(R) (lansoprazole) and Lupron Depot(R) (leuprolide acetate for depot suspension). For more ... - PR Newswire (press release),

Flamel Technologies Announces Notification of Termination of the ...  Sep 5, 2005
...on September 2, 2005 which is a notice of termination of the license of Flamel's Micropump(R) technology for use in the delivery of lansoprazole, the active ... - Business Wire (press release),

TAP Initiates Phase III Studies for Investigational New ...  Aug 29, 2005
Licensed from Takeda Pharmaceutical Company Limited, TAK-390MR employs a new modified release (MR) technology on an enantiomer of lansoprazole. ... - Yahoo News (press release)

UPDATE 3-Takeda Prevacid's successor to start Phase 3 trial  Aug 30, 2005
...it to skip Phase II clinical trials because the molecular structure of TAK-390MR is a mirror image of Prevacid, known generically as lansoprazole, which had ... - Reuters

Takeda Pharmaceutical Starts Phase III Clinical Study of TAK-390MR ...  Aug 31, 2005
...the US. TAK-390 is a drug candidate for the treatment of peptic ulcer, which is based on a proton pump inhibitor lansoprazole. By ... - Japan Corporate News (press release),

Pain Management/GI Combination Pill Wins Patent 8/18/05  Aug 17, 2005
In an initial comparison of PN 100, a combination tablet of lansoprazole and naproxen, against naproxen and co-therapy of a PPI, they found a significant ... - Bioscience Technology,

American College of Gastroenterology Announces 2005 Junior Faculty ...  Aug 16, 2005
...of Osaka, Japan. TAP currently markets Lupron Depot(r) (leuprolide acetate for depot suspension) and Prevacid(r) (lansoprazole). ... - U.S. Newswire (press release),

Norwood Immunology -- Publication in Leading Scientific Journal  Aug 11, 2005
Company Limited of Osaka, Japan. TAP currently markets Lupron Depot and Prevacid(R) (lansoprazole). For more information about TAP ... - Genetic Engineering News,

James Le Fanu on the power of genes  Aug 18, 2005
...into the lungs. Within a week of starting the acid-suppressant drug Lansoprazole, "my cough had vanished", she writes. There are ... - Telegraph.co.uk,

Cooking to Reduce the Burn: Heartburn-Friendly Recipes and Tips ...  Aug 2, 2005
...you.". Cooking to Reduce the Burn is sponsored by TAP Pharmaceutical Products Inc., the distributor of Prevacid®, (lansoprazole). ... - Yahoo News (press release)

Abbott Reports 17.5 Percent Sales Increase in the Second Quarter  Jul 13, 2005
...$219 22.9 Synthroid $113 (36.1) $14 (9.7) $127 (34.0) Omnicef* $85 62.8 --- -- $85 62.8 Leuprolide --- -- $57 17.2(d) $57 17.2 Lansoprazole --- -- $37 5.7(e ... - Yahoo News (press release)

FDA Safety Labeling Changes: Plavix, Sustiva, Prevpac  Jul 13, 2005
...purpura; exposure to efavirenz during the first trimester of pregnancy may cause fetal harm; and the antibiotic components of a lansoprazole, amoxicillin, and ... - Medscape (subscription)

Lansoprazole is metabolized through the cytochrome P₄₅₀ system, specifically through the CYP3A and CYP2C19 isozymes. Studies have shown that lansoprazole does not have clinically significant interactions with other drugs metabolized by the cytochrome P₄₅₀ system, such as warfarin, antipyrine, indomethacin, ibuprofen, phenytoin, propranolol, prednisone, diazepam, clarithromycin, or terfenadine in healthy subjects. These compounds are metabolized through various cytochrome P₄₅₀ isozymes including CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A. When lansoprazole was administered concomitantly with theophylline (CYP1A2, CYP3A), a minor increase (10%) in the clearance of theophylline was seen. Because the small magnitude and the direction of the effect on theophylline clearance, this interaction is unlikely to be clinical concern. Nonetheless, individual patients may require additional titration of their theophylline dosage when lansoprazole is started or stopped to ensure clinically effective blood levels.

Lansoprazole has also been shown to have no clinically significant interaction with amoxicillin.

In a single-dose crossover study examining lansoprazole 30 mg and omeprazole 20 mg each administered alone and concomitantly with sucralfate 1 gram, absorption of the proton pump inhibitors was delayed and their bioavailability was reduced by 17% and 16%, respectively, when administered concomitantly with sucralfate. Therefore, proton pump inhibitors should be taken at least 30 minutes prior to sucralfate. In clinical trials, antacids were administered concomitantly with lansoprazole delayed-release capsules; this did not interfere with its effect.

Lansoprazole causes a profound and long lasting inhibition of gastric acid secretion; therefore, it is theoretically possible that lansoprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g. ketoconazole, ampicillin esters, iron salts, digoxin).